TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02739334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENRICH
Description: The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - monthly handouts
Description: The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
Study: NCT02284958

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Back care advice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Back care advice, individualized 12 week pedometer-driven walking program
Study: NCT00392171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
Study: NCT02710968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 11540KE and Balt Goldbal 2 balloon
Description: Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
Study: NCT00843297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coolgard
Description: invasive Cooling via femoral ICY-catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArcticSun
Description: Noninvasive surface-cooling by saline-cooled thermo-vest

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Intensive care-treatment without cooling
Study: NCT02689219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Both cohorts will be treated similarly and in parallel but analyzed separately.
Study: NCT00795847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preminent (losartan/hydrochlorothiazide combination drug)
Description: Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preminent (losartan/hydrochlorothiazide combination drug)
Description: Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
Study: NCT03383458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: specified dose on specified days
Study: NCT03687112

Intervention type: OTHER
Intervention: non ontervention / observational study
Description: non intervention
Study: NCT01596387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
Study: NCT01104571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT03081975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD white light or NBI
Description: Use of NBI or HD white light

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD white light or NBI
Description: Use of NBI or HD white light
Study: NCT00066729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 peptide vaccine
Description: NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51
Study: NCT05766098

Intervention type: GENETIC
Intervention: Genotyping
Description: Characterization of genetic profile of tumor tissues
Study: NCT03529019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensure Surgery Immunonutrition Shake
Description: An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensure Enlive Advanced Nutrition Shake
Description: An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
Study: NCT01104571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Description: therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Description: therapeutic conventional surgery
Study: NCT03340792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulation training utilizing an exoskeleton robot
Description: Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
Study: NCT02114112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP cycling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP continuous
Study: NCT00925873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator (no fludarabine)
Description: 1. Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~2. The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~3. Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental (fludarabine)
Description: The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2.
Study: NCT03069417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrating Nuanced Support for Perinatal adherence and Depression
Description: A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrating Nuanced Support for Perinatal adherence and Depression
Description: A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
Study: NCT00527917

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: bladder instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uracyst
Description: 20 ml sterile solution for weekly intravesical instillation
Study: NCT02045524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep muscle injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-Q Injection
Study: NCT04640012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC371739
Description: Participants received one of 6 dose levels of DC371739 administered as single oral doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered
Study: NCT01590251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Counseling
Description: One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
Study: NCT02050035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
Study: NCT04418531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients
Description: Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
Study: NCT02247518

Intervention type: DRUG
Group type: OTHER
Intervention: Cialis Tab. 5mg

Intervention type: DRUG
Group type: OTHER
Intervention: Cialis Tab. 5mg

Intervention type: DRUG
Group type: OTHER
Intervention: Harnal-D Cap. 0.2mg

Intervention type: DRUG
Group type: OTHER
Intervention: Harnal-D Cap. 0.2mg
Study: NCT00047047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01143831

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K, 20mg
Description: Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
Study: NCT00889252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contact lens with ketotifen
Description: K-Lens (generic name not established) and Ketotifen combination drug-device product

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: contact lens
Description: Placebo contact lens
Study: NCT01527838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single FT1050 treated UCB unit
Description: Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
Study: NCT02941588

Intervention type: PROCEDURE
Intervention: Non-cardiac surgery
Description: Any surgery with general anesthesia except cardiac surgery
Study: NCT05183711

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
Study: NCT03474133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
Study: NCT01166412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2
Description: 6.5mg patch daily for 11 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI <32 kg/m2
Description: 6.5mg patch daily for 11 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2
Description: 12.5mg patch daily for 11 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel patch with BMI <32 kg/m2
Description: 12.5mg patch daily for 11 weeks
Study: NCT01595737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
Study: NCT01905319

Intervention type: OTHER
Intervention: Blood collecting for storage of samples
Study: NCT01975766

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Study: NCT02918487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyherbal
Description: Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyherbal
Description: Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive compound that is similar looking as the intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive compound that is similar looking as the intervention
Study: NCT00658372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
Study: NCT03879447

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.

Intervention type: PROCEDURE
Intervention: Chuna manual medicine
Description: Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.

Intervention type: PROCEDURE
Intervention: Chuna manual medicine
Description: Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
Study: NCT00658372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 300 mg BID, 8 weeks with 2 week taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, oral, placebo, BID, 8 weeks with 2 week taper
Study: NCT01333202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh lime
Description: fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh lime
Description: fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
Study: NCT01426087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: giving stilamin 250ug/h after endoscopic therapy for 5 days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic therapy
Description: gastroscope plus EIS/EVL/HI
Study: NCT02262559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 277 capsule
Study: NCT01985464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Study: NCT02546024

Intervention type: DRUG
Intervention: Standard care
Description: Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust

Intervention type: DRUG
Intervention: Standard care
Description: Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
Study: NCT02320162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential learning oral health education

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experiential learning oral health education
Study: NCT03052855

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) and biological samples
Description: Participants will have to do a MRI and biological samples.
Study: NCT03496987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Bottle Drainage
Description: Patients undergo drainage via vacuum bottles
Study: NCT01589640

Intervention type: OTHER
Intervention: Blink Tears lubricating Eye Drops
Description: 2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)

Intervention type: OTHER
Intervention: Blink Gel Tears Lubricating Eye Drops
Description: 2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)

Intervention type: OTHER
Intervention: Systane Balance Lubricant Eye Drop
Description: 2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
Study: NCT00723632

Intervention type: BIOLOGICAL
Intervention: peginterferon alfa-2b
Description: Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.

Intervention type: DRUG
Intervention: ribavirin
Description: Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants \<65 kg, 1000 mg/day for participants \>65 to \<85 kg, and 1200 mg/day for participants \>=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
Study: NCT02756585

Intervention type: RADIATION
Group type: OTHER
Intervention: ct perfusion
Description: computed tomography perfusion of the head
Study: NCT02019849

Intervention type: DEVICE
Intervention: Plasmafit® Total Hip Arthroplasty
Study: NCT01838733

Intervention type: OTHER
Intervention: Observational study
Study: NCT00761137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg tropicamide
Description: 0.3 mg tropicamide in intra-oral thin film
Study: NCT03638622

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
Study: NCT01435902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol Inhalation Powder
Description: Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
Study: NCT00761137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg tropicamide
Description: 0.3 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg tropicamide
Description: 0.3 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg tropicamide
Description: 1 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg tropicamide
Description: 1 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg tropicamide
Description: 1 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg tropicamide
Description: 1 mg tropicamide in intra-oral thin film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg tropicamide
Description: 3 mg tropicamide in intra-oral thin film
Study: NCT01435902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Inhalation Powder
Description: Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks